NasdaqGS:NVAXBiotechs
Assessing Novavax (NVAX) Valuation After Strong 2025 Results And Return To Profitability
Novavax (NVAX) just released fourth quarter and full year 2025 results, reporting revenue of US$147.14 million for the quarter and US$1.12 billion for the year, alongside full year net income of US$440.3 million.
See our latest analysis for Novavax.
Those stronger 2025 earnings come at a time when momentum in the share price has picked up, with a 30 day share price return of 24.14% and a year to date share price gain of 51.47%. However, the 5 year total shareholder return of a 95.21% decline...